Welcure Drugs & Pharmaceuticals Ltd

524661

Summary

Fair Value Assessment
Overvalued (6% Premium)
Fair ValueQ9.01UncertaintyHigh
Close Price9.64Mar 25, 2025
9.45
Price Down by 0.19 | 1.97 %
Previous Close
9.64
Day Range
9.45 – 9.45
Year Range
3.76 – 15.81
Bid / Ask
Market Cap
1.1 Bil
Volume / Average
1.9 k / 73.4 k
Beta (5-Year)
0.41
Shares Outstanding
112.51 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
Welcure Drugs & Pharmaceuticals Ltd is a pharmaceutical company. The company is principally engaged in the manufacturing of pharmaceutical products. The company has one operating segment: Providing services for procurements of order.
Contact
Laxmi Nagar, Plot No. 55 Office No. 104, First Floor, Vijay Block, Delhi, Delhi 110092
T +91 1127011428
welcuredrugs.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Dec 31, 2024
Fiscal Year End
Mar 31, 2025
Employees

Key Metrics

Income Statement (in Mil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Revenue
333.88 1.05 1.33 0.83
Revenue Growth %
-21.26% 61.58% 3.77%
Gross Profit
Gross Profit Margin %
Operating Income
22.93 -2.66 -1.35 0.24 0.55 -0.10
Operating Margin %
6.87% 22.52% 41.19% -11.76%
EBIT
23.30 -2.33 0.57 0.24 0.55 -0.10
EBIT Margin %
6.98% 22.46% 41.19% -11.86%
EBITDA
23.63 -1.97 0.60 0.24 0.55 -0.10
EBITDA Margin %
7.08% 22.46% 41.19% -11.86%
Net Income
18.89 -1.75 1.02 0.24 0.55 -0.09
Net Profit Margin %
5.66% 22.46% 41.34% -11.43%
Basic EPS
0.05 -0.13 0.08 0.02 0.05 -0.01
Diluted EPS
0.05 -0.13 0.08 0.02 0.05 -0.01
Normalized EPS
Total Dividends per Share
Balance Sheet (in Mil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Total Assets
2,698.40 13.71 15.29 0.97 0.73 0.25
Total Liabilities
1,680.06 0.31 0.14 0.04 0.04 0.10
Total Debt
Total Equity
1,018.34 13.40 15.15 0.93 0.69 0.14
Cash And Cash Equivalents
2.27 0.22 0.01 0.66 0.48 0.05
Working Capital
1,004.16 0.01 -0.08 0.62 0.69 0.14
Shares Outstanding (Mil)
13.51
Book Value Per Share
0.99 1.12 0.07 0.05 0.01
Total Debt To Equity
Cash Flow Statement (in Mil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
-986.93 -1.28 1.07 0.19 0.42 -0.10
Cash From Investing Activities
2.24 1.65 13.21
Cash From Financing Activities
990.18 -0.17 -14.92
Capital Expenditures
Free Cash Flow
-1.39 1.02 0.24 0.55 -0.09
Change in Cash
5.48 0.20 -0.65 0.19 0.42 -0.10

Profile

There is no Key Executive Team data available.
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
No Data Available
There is no available information for this investment.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
No Data Available
There is no available information for this investment.

Ownership

There is no Ownership data available.

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top